MiNK Therapeutics, Inc.
INKT
Some of our competitors have initiated clinical trials for GvHD, solid tumors and multiple myeloma, settings in which our iNKT cell therapy platform is currently being investigated. We are also aware of competitors pursuing cell therapy drug candidates, including but not limited to stem cell-based approaches, for the treatment of ARDS secondary to COVID-19.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$11M
▼ -15.9% YoY
Op. Margin
–
ROIC
–
Cash Flow & Balance Sheet
FCF (TTM)
-$7M
▲ +38.0% YoY
Op. Cash Flow (TTM)
-$7M
▲ +38.0% YoY
Net Debt
-$7M
Net Cash Position
Cash & Equiv.
$7M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with INKT
MiNK Therapeutics (INKT) in two numbers
Questions about MiNK Therapeutics
Does MiNK Therapeutics (INKT) pay a dividend?
No. MiNK Therapeutics (INKT) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 6 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in INKT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing INKT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.